Compare Alcon AG (ALC) vs ThredUp Inc (TDUP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs ThredUp Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while ThredUp Inc trades at $6.49 (market cap $882.64M). The key difference: Alcon AG is far larger — about 37× ThredUp Inc's market cap, and Alcon AG pays a 0.54% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| ALC | TDUP | |
|---|---|---|
Market Cap | $32.69B | $882.64M |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $12.08 |
52-Week Low | $62.02 | $3.11 |
Enterprise Value | $36.28B | $885.37M |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
TDUP trades at $6.84, down 2.7% today, with a consensus price target of $6.90. The stock shows bullish technical signals from moving averages, though oscillators are neutral. Recent Q1 2026 results met EPS expectations with record active buyers and 15% revenue growth. The company maintains a high gross margin of 79.4% but continues to report net losses, with improving cash flow from operations turning positive in 2025.
Investment outlook remains cautiously optimistic given analyst consensus (57% buy ratings) and recent business initiatives including AI integration and marketplace expansion. Key risks include persistent unprofitability and competitive pressures in resale markets. The stock presents potential for growth if margin improvements continue, but requires monitoring of earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
